On CNBC's "Mad Money Lightning Round," Jim Cramer said that Bed Bath & Beyond Inc. (NASDAQ: BBBY) was deemed nonessential and he thinks that it's going to be tough for it to come back. He added that it does have a capital and it can try to last.Cramer has always liked TE Connectivity Ltd (NYSE: TEL) and he would own the stock.He is not recommending the oil companies, but he thinks it's fine for his viewer to own Pioneer Natural Resources (NYSE: PXD).Cramer sees B&G Foods, Inc. (NYSE: BGS) as mini-Kraft Heinz Co (NASDAQ: KHC). The brand seems tired to him.Digital Realty Trust, Inc. (NYSE: DLR) is a data center REIT and Cramer likes it.Citrix Systems, Inc. (NASDAQ: CTXS) is a good stock, said Cramer. It's consolidating now and he finds that positive.Cramer prefers Dropbox Inc (NASDAQ: DBX) over Box Inc (NYSE: BOX).Co-Diagnostics Inc (NASDAQ: CODX) is too controversial and Cramer needs to do more work on the stock.Cramer continues to like GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH). It's medical cannabis and it's the only one doctors really use because it has a dosage.See more from Benzinga * Cramer Shares His Thoughts On Broadcom, Bed Bath & Beyond And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

These are the NASDAQ-listed marijuana stocks with the best value, fastest growth, and most momentum for April.

GW Pharmaceuticals (GWPH) might have registered slower international sales growth from procedural deferrals due to coronavirus pandemic in Q1.

Cannabinoid prescription medicines stock GW Pharmaceuticals (GWPH) has reported particularly strong first quarter earnings results, with US sales of Epidiolex at $116.1M, up over 215%. This cannabidiol oral solution is approved in the US and Europe for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older.First quarter GAAP EPS of -$0.02 beat Street expectations by $0.05, and revenue of $120.6M (up an eye-watering 207.3% year-over-year) beat by $15.5M. GWPH shares popped 9% in after-market trading on Monday, bringing the stock’s year-to-date gain to 4%.“In the first quarter of 2020, we have seen continued strength of the Epidiolex brand in both the U.S. and Europe and remain confident about prospects for growth in the remainder of the year,” stated Justin Gover, GW’s CEO.For the second quarter, management noted a “solid” April for US Epidiolex sales and expects flat to modest growth throughout the quarter in the US, due to the current environment. GWPH’s global manufacturing and supply chain is currently uninterrupted by COVID-19.Looking ahead, GW Pharma has also submitted applications in both the US and Europe to expand the indication for Epidiolex to include seizures associated with Tuberous Sclerosis Complex (TSC), for which it has reported positive Phase 3 data, and is carrying out a Phase 3 trial in Rett syndrome.“Having been granted priority review by the FDA for our proposed label expansion to include TSC, our US commercial team is actively preparing for the launch of this indication in August” Gover said. The FDA action date is July 31.“With further potential upside levers in the near-term (launch progress, TSC label expansion) and mid- to long-term (off-label use, Epidiolex IP extension beyond 2027, and pipeline/nabiximols progress), we continue to see a favorable set up for GWPH” cheered JP Morgan’s Cory Kasimov following the results. He has a buy rating on the stock and $187 price target (71% upside potential).“Near-term label expansion opportunities (Tuberous Sclerosis) and the potential for off-label use in the broader population of general epilepsy patients could contribute significantly to the top line” he continued.Indeed, GWPH boasts a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which it is advancing multiple late-stage clinical programs for the treatment of spasticity and PTSD. It also has additional cannabinoid product candidates in Phase 2 trials for autism and schizophrenia.Overall the stock has a firm Strong Buy analyst consensus with 12 recent buy ratings- and no hold or sell ratings. The average analyst price target stands at $177 (62% upside potential). (See GWPH stock analysis on TipRanks).Related News: Qantas Said to Halt Plane Deliveries From Boeing, Airbus Amid Travel Freeze 3 Stocks Needham’s Top Analysts Are Raving About AMC Pops 11% Amid Potential Acquisition Talks by Amazon More recent articles from Smarter Analyst: * Microsoft Buys Softomotive To Boost Its Robotic Automation Offerings * Spotify Surges 8.4%, Joe Rogan Brings More Than Experience Says Top Analyst * Microsoft Launches Cloud-Based Platform For Healthcare Organizations * Cisco’s Results Disappoint, Revealing a Challenging April

Like many stocks, GW Pharmaceuticals (NASDAQ: GWPH) took a beating in the coronavirus-fueled market sell-off earlier this year. GW Pharmaceuticals announced its first-quarter results after the market closed on Monday. Here's how GW hit a home run in Q1.

Demand for the marijuana drug developer's treatment for epilepsy caused shares to skyrocket last quarter.

Healthcare investors can look past the development risk. Global Blood Therapeutics (NASDAQ: GBT) crushed analyst estimates when it reported its first-quarter results on May 6. In its first full quarter on the market, Global Blood's sickle cell disease drug Oxbryta posted $14.1 million in net sales.

GW Pharmaceuticals (NASDAQ: GWPH) is a crossbreed: a biotech and a cannabis company. Based in England and founded in 1998, the company's focus is examining various cannabinoid formulations as potential therapeutics. GW Pharmaceuticals's biggest drug is Epidiolex, a liquid, purified form of cannabidiol (CBD).

There are some attractive options for growth investors, even amid the rout in the broader cannabis sector.

- Total revenue of $120.6 million - - Total Epidiolex® net product sales of $116.1 million - - Conference call today at 4:30 p.m. EDT – LONDON and CARLSBAD, Calif., May 11,.

GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the Bank of America Healthcare Conference 2020 on Tuesday, May 12th, 2020 at 1:40pm EST, which is being held virtually. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.

Sales of GW Pharmaceuticals' seizure medicine, Epidiolex, easily topped Wall Street's first-quarter expectations Monday, leading GWPH stock to pop. Losses were also better than expected.

GW Pharmaceuticals PLC shares rose 2.6% in the extended session Monday after the U.K.-based company sold much more of its cannabis derived epilepsy drug, Epidiolex. The company reported a first-quarter net loss of $8 million, or 2 cents a share, compared with a loss of $50.1 million, or 14 cents a share, a year ago. Revenue rose to $120.6 million from $39.2 million in the year-ago period. The company's most popular drug, a cannabis-derived medicine used to treat epilepsy, logged sales of $116.1 million, topping analyst expectations of $106.9 million, according to FactSet's survey. Wall Street expected an adjusted net loss of 7 cents a share on sales of $108.4 million. GW Pharma stock has inched up 4.7% this year as the benchmark S&P 500 index has fallen 9.3%.

Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it has bolstered its Board of Directors with the appointments of Prof. Dr. Gerd Auffarth and Mr. Julian Gangolli. “We are incredibly pleased to add individuals of Dr. Auffarth’s and Mr. Gangolli’s caliber to the Outlook Therapeutics Board of Directors,” stated Lawrence A. Kenyon, President, CEO and CFO, Outlook Therapeutics.

After netting nearly $1 billion in profits in 2019, cannabis short sellers got off to a strong start in 2020 as well. However, cannabis stocks have taken off in recent weeks, and cannabis short sellers are feeling the pain.What HappenedS3 Partners analyst Ihor Dusaniwsky said Thursday that cannabis short sellers are down $641 million in the month of May, and their year-to-date profits are down to just $180.1 million.Dusaniwsky said S3's portfolio of 240 U.S. and Canada-listed cannabis stocks currently has $2.8 billion in total short interest. In the past week, Dusaniwsky said short sellers have added $76 million to their positions.To make matters worse for cannabis short sellers, borrow fees have been on the rise. Dusaniwsky said average borrow fees for the top 20 most shorted cannabis stocks are up 12.8% over the past month to 32.1%. Cannabis short sellers are now paying more than $2.55 million in daily financing cost.Don't miss this opportunity to connect with THE cannabis movers and shakers from across the globe during Benzinga's first Virtual Cannabis Capital Conference on June 1.Most Shorted Cannabis Stocks Here are the five most heavily shorted cannabis stocks today by short interest, according to S3: * Canopy Growth Corp (NYSE: CGC), $913.7 million. * GW Pharmaceuticals PLC (NASDAQ: GWPH), $656.1 million. * Aurora Cannabis Inc (NYSE: ACB), $186.8 million. * Cronos Group Inc (NASDAQ: CRON), $307.3 million. * Aphria Inc (NYSE: APHA), $143.5 million.Dusaniwsky said traders looking for the most likely short squeeze candidates should focus on stocks with the highest borrow fees that have generated the biggest losses for short sellers year to date."Mark-to-market losses coupled with rising stock borrow rates are priming the pump for potential short squeezes in several cannabis stocks," Dusaniwsky wrote.Aurora may be the top candidate for a squeeze given the stock's high borrow rate and the heavy losses inflicted on short sellers in the past month.Benzinga's TakeGiven the volatility and unpredictability in the cannabis group and the fact that it's so expensive just to maintain a position, shorting cannabis stocks in 2020 is very risky business. Short sellers still sitting on large cannabis gains from 2019 should consider taking profits on at least a portion of their positions.Related Links:Here's How Much Investing 0 In The 2018 Cronos Listing Would Be Worth Today How Legalizing Marijuana Could Help Kick-Start The US EconomyLatest Ratings for CGC DateFirmActionFromTo Feb 2020Stifel NicolausMaintainsBuy Jan 2020BMO CapitalUpgradesMarket PerformOutperform Nov 2019Bank of AmericaUpgradesNeutralBuy View More Analyst Ratings for CGC View the Latest Analyst RatingsSee more from Benzinga * 7 Sin Stocks To Buy During The Coronavirus Shutdown * How Trading In Ford, GE And Other Volatile Stocks Could Be Linked To Casino Closures(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on May 11th, 2020 its financial results for the first quarter ending March 31st, 2020. GW will also host a conference call the same day at 4:30 p.m. ET. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

If you're interested in GW Pharmaceuticals plc (NASDAQ:GWPH), then you might want to consider its beta (a measure of...

GW Pharmaceuticals plc (NASDAQ: GWPH) confirmed Monday it has obtained a notice from the Drug Enforcement Administration certifying that its Epidiolex oral solution has been descheduled and is no longer a controlled substance."This notification from DEA fully establishes that EPIDIOLEX, the only CBD medicine approved by FDA, is no longer a controlled substance under the federal Controlled Substances Act," GW Pharma CEO Justin Gover said in a statement.Gover thanked the DEA for confirming "the non-controlled status" of the medicine."Importantly, the descheduling of EPIDIOLEX has the potential to further ease patient access to this important therapy for patients living with Lennox-Gastaut Syndrome and Dravet syndrome, two of the most debilitating forms of epilepsy," he said.Leer en Español: Epidiolex, la Droga con CBD para Epilepsia, se Abre Camino LegalAfter obtaining the DEA notice, the Cambridge, U.K.-based company said it has filed a post-approval supplement with the FDA to lift the Schedule V designation from the drug. GW Pharma said it is now working on enforcing these amendments at the state level and via the Epidiolex distribution network.Once all the changes have been enacted, the drug can be prescribed just like any other non-controlled medicine, with a prescription being valid for one year. This allows doctors to prescribe the drug more freely, without the demands of state prescription drug monitoring programs, according to GW. GW Pharma shares were trading 4.66% higher at $90.62 at the time of publication Tuesday.Related Links: GW Pharma Vet Ethan Russo Launches Endocannabinoid StartupGW Pharma Obtains Exclusive UK Commercialization Rights To Sativex From BayerPhoto courtesy of GW Pharmaceuticals.See more from Benzinga * GW Pharma Vet Ethan Russo Launches Endocannabinoid Startup * GW Pharma Submits CBD Seizure Treatment To European Medicines Agency For Approval(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

GWPH earnings call for the period ending March 31, 2020.

In the fast-paced Lightning Round segment of Mad Money Wednesday night one caller asked Jim Cramer about GW Pharmaceuticals plc . "This is the only medical cannabis and I continue to like GW Pharma," Cramer replied. In the daily bar chart of GWPH, below, we can see some positive clues and some bullish divergences.